Gut‐specific inhibition of PPARα as a novel approach of NAFLD treatment
Lanjing Zhang, Grace L. Guo – 26 May 2022
The unfolded protein response to PI*Z alpha‐1 antitrypsin in human hepatocellular and murine models
Yuanqing Lu, Liqun R. Wang, Jungnam Lee, Naweed S. Mohammad, Alek M. Aranyos, Calvin Gould, Nazli Khodayari, Regina A. Oshins, Craig G. Moneypenny, Mark L. Brantly – 26 May 2022 – Alpha‐1 antitrypsin (AAT) deficiency (AATD) is an inherited disease caused by mutations in the serpin family A member 1 (SERPINA1, also known as AAT) gene. The most common variant, PI*Z (Glu342Lys), causes accumulation of aberrantly folded AAT in the endoplasmic reticulum (ER) of hepatocytes that is associated with a toxic gain of function, hepatocellular injury, liver fibrosis, and hepatocellular carcinoma.
Issue Information
25 May 2022
Liver transplantation in tight junction protein‐2 deficiency associated liver disease
Jagadeesh Menon, Naresh Shanmugam, Mukul Vij, Ashwin Rammohan, Mohamed Rela – 25 May 2022
Pretransplant management of the patient with severe acute‐on‐chronic liver failure
Bhupinder Kaur, Andres Cardenas, Constantine J. Karvellas – 25 May 2022
Pretransplant management of the patient with severe acute‐on‐chronic liver failure
Bhupinder Kaur, Andres Cardenas, Constantine J. Karvellas – 25 May 2022
Response to Tinospora cordifolia (Giloy)‐induced liver injury during the COVID‐19 pandemic—Multicenter nationwide study from India
Geethalayam G. Gangadharan, Vinay Mahajan – 25 May 2022
The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma
Isabella Lurje, Zoltan Czigany, Sarah Eischet, Jan Bednarsch, Tom Florian Ulmer, Peter Isfort, Pavel Strnad, Christian Trautwein, Frank Tacke, Ulf Peter Neumann, Georg Lurje – 25 May 2022 – Cholangiocarcinoma (CCA) is a rare but highly aggressive malignancy of the biliary system. Although it is amenable to surgical resection in early disease, outcomes are frequently dismal. Here, we investigated the prevalence of body composition (BC) alterations and their prognostic role for surgical patients with intrahepatic (iCCA) and perihilar (pCCA) disease.
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers
Zachary M. Saleh, Elliot B. Tapper – 25 May 2022
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis
Claire Harrington, Swathi Krishnan, Cara L. Mack, Paolo Cravedi, David N. Assis, Josh Levitsky – 24 May 2022 – Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self‐tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First‐line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking.